Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what provision the National Cancer Plan will make for orphan drug pathways for patients with rare cancers requiring personalised treatment plans; and how those pathways will differ from existing commissioning arrangements.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On 4 February 2026, NHS England and the Department published a National Cancer Plan for England. The National Cancer Plan is part of our work to build a National Health Service that is fit for the future and will make England a world-leader for cancer survival.
The orphan drug designation is assessed by the Medicines and Healthcare products Regulatory Agency and is granted at the same time as the marketing authorisation. It provides a period of market exclusivity during which similar competitor medicines cannot enter the United Kingdom market. The orphan drug regulations are designed to support the development of medicines to treat rare diseases including rare cancers.
All new licensed medicines, including orphan medicines, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the NHS on whether they represent a clinically and cost-effective use of NHS resources. NICE aims wherever possible to issue recommendations on new medicines close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE. NICE has a strong track record in recommending orphan medicines for use on the NHS and many thousands of patients with rare diseases have benefitted from access to new medicines as a result.
The Rare Cancers Bill, currently going through the House of Lords, places a duty on the Government to publish a review of the law related to marketing authorisation for rare cancer drugs, for instance orphan drugs for cancer, comparing the UK’s approach to other approaches internationally. Through the National Cancer Plan the Government has committed to full implement of the Rare Cancers Bill to streamline trial pathways and review regulatory barriers that prevent access to promising new treatments.
Asked by: Tom Hayes (Labour - Bournemouth East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is the Department taking to remove barriers preventing community homelessness health services, such as mobile clinics, from accessing NHS SystemOne records.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
It is important that community health teams can access the information they need to provide quality care, including for people who are experiencing homelessness. NHS England and the Phoenix Partnership (TPP), the company that provides SystemOne, already offer several routes for some clinicians to view records outside of GP settings.
These include national services such as GP Connect and the National Care Records Service (NCRS), which allow clinicians to see key information from GP records. NCRS can also be used on mobile devices such as iPads. Integrated care systems are rolling out Shared Care Records, which give clinicians wider access to both GP and secondary care records, where appropriate.
More broadly, the Government’s commitments to improve health outcomes for people experiencing homelessness are set out in the cross-government strategy, A National Plan to End Homelessness. Through this strategy, we are working with NHS England, local authorities, and third sector partners to strengthen integrated care pathways. This includes improving collaboration between primary care, outreach teams, and community services. More information about the strategy is available at the following link:
The Single Patient Record will enable improvements as it will provide a comprehensive view of health and care information across care settings. It will give both patients and professionals secure access to a single, accurate and up-to-date record – wherever and whenever it's needed.
Asked by: Cat Smith (Labour - Lancaster and Wyre)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to publish updated guidance on managing conflicts of interest between civil servants and Ministers in relation to unhealthy commodity industries.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department already has established arrangements in place to manage conflicts of interest for both ministers and civil servants, including where these relate to engagement with representatives of unhealthy commodity industries.
Ministerial conduct is governed by the Ministerial Code, which sets out requirements on the declaration and handling of ministers’ interests. Civil servants are bound by the Civil Service Code, and by departmental policies that set out how actual, potential, or perceived conflicts of interest must be identified, declared, and managed.
The Department keeps its internal guidance under regular review to ensure it remains aligned with cross-Government standards and supports transparent and accountable decision-making.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the performance of AJM Healthcare in delivering wheelchair services to the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The safety of all patients, whether they are treated in the National Health Service or the independent sector, is a top priority for the Government. There are a range of providers of NHS wheelchair services across England. Integrated care boards (ICBs) are responsible for monitoring service provision and effectively managing contracts with their commissioned providers.
NHS England are aware there have been a number of separate complaints about the quality of services provided by AJM Healthcare, which are being dealt with on an individual basis by the Ombudsman’s office. NHS England has flagged this to the relevant ICBs, who are responsible for the provision and commissioning of local wheelchair services. NHS England supports ICBs to make improvements and commission effective, efficient, and personalised wheelchair services. Actions taken include:
- establishing a national wheelchair dataset, where data has been collected quarterly from ICBs, formerly clinical commissioning groups, since July 2015 and which supports the drive for improvements in wheelchair services. This data looks at waiting times across the pathway to enable targeted action if improvement is required. Further information is available at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/national-wheelchair/
- the Wheelchair Quality Framework, which was published on the 9 April 2025, and which was co-produced with key stakeholders, including Whizz Kids. The framework sets out quality standards and statutory requirements for ICBs, such as offering personal wheelchair budgets, with further information available at the following link:
https://www.england.nhs.uk/long-read/wheelchair-quality-framework/
- personal wheelchair budgets, with NHS England having introduced personal wheelchair budgets, including in legal rights, in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided, with further information available at the following link:
https://www.england.nhs.uk/publication/guidance-on-the-legal-rights-to-have-personal-health-budgets-and-personal-wheelchair-budgets/
Asked by: Tim Farron (Liberal Democrat - Westmorland and Lonsdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of poor air quality in (a) ambient air and (b) indoor air on different age groups of people in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Poor air quality is a major public health risk in the United Kingdom. An estimated 29,000 to 43,000 deaths were attributable to long-term exposure to ambient air pollution in the UK in 2019 among adults aged 30 years old and over.
Indoor residential exposure to damp and mould was associated with approximately 5,000 cases of asthma and 8,500 lower respiratory infections among children, those who are aged between zero to 14 years old, and adults, those who are aged between 15 to 49 years old, in England in 2019.
The UK Health Security Agency (UKHSA) contributed to a report by the Royal College of Physicians in 2025. This contained data on new cases of mortality, myocardial infarction, asthma, lung cancer, and other conditions, attributable to a range of air pollutants in 2019 and predicted for 2040, among children, those over 30 years old, over 60 years old, and at all ages. The report is available at the following link:
The Department’s 10-Year Health Plan sets out how the Government will act to reduce the health harms of air pollution. This includes action to reduce harm from ambient air pollution and tackling poor indoor air by improving the standard of rented homes with relation to damp and mould.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that increased medicine prices do not have an adverse impact on NHS activity.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector to increase access to life-changing medicines without taking essential funding from our frontline NHS services.
We will always prioritise the needs of NHS patients and at the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029.
This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.
Asked by: Stuart Anderson (Conservative - South Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to reply to the email from the hon. Member for South Shropshire dated 24 October 2025 with case reference number SA36602.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has received the Hon. Member’s letter and I will respond shortly.